429
Participants
Start Date
September 22, 2022
Primary Completion Date
December 30, 2030
Study Completion Date
December 30, 2032
Osivelotor
Tablets which contain drug substance
Children's National Hospital, Washington D.C.
Inova Schar Cancer Institute, Fairfax
UNC Health, Chapel Hill
Sonar Clinical Research, Atlanta
Alpha Clinical Research Georgia, Dunwoody
Edward Jenner Research Group Center LLC, Plantation
Pediatric Hematology / Oncology a division of Kidz Medical services, West Palm Beach
Mississippi Center for Advanced Medicine, Madison
KEMRI/CRDR, Siaya, KEMRI Clinical Research Annex, Kisumu
University of Illinois at Chicago Clinical Research Center, Chicago
University Health, Kansas City
University Medical Center New Orleans, New Orleans
LSU Health Baton Rouge-North Clinic, Baton Rouge
McGovern Medical School at UTHealth, Houston
Aminu Kano Teaching Hospital, Kano
Smilow Cancer Hospital, New Haven
Hospital Universitario Professor Edgar Santos, Salvador
Multihemo Servicos Medicos S/A, Recife
Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, São José do Rio Preto
Esho Empresa De Servicos Hospitalares S.A/ Hospital Samaritano Higienopolis, São Paulo
Real e Benemerita Associacao Portuguesa de Sao Paulo, São Paulo
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo
Center for Research In Therapeutic Sciences (CREATES), Strathmore University Medical Centre, Nairobi
Lead Sponsor
Pfizer
INDUSTRY